A randomized noncomparative phase II study of maintenance therapy with multiepitope vaccine Tedopi (OSE2101) ± nivolumab or FOLFIRI after induction chemotherapy (CT) with FOLFIRINOX in patients (Pts) with advanced pancreatic ductal adenocarcinoma (aPDAC) (TEDOPaM PRODIGE 63 GERCOR D17-01 study)

ANNÉE

2019

AUTEURS

Neuzillet C, Hautefeuille V, Lambert A, Garcia-Larnicol ML, Vernerey D

CONGRÈS/REVUE

ASCO

LIEN PUBLICATIONS ASSOCIÉES